Lupin is currently trading at Rs. 875.95, up by 12.60 points or 1.46% from its previous closing of Rs. 863.35 on the BSE.
The scrip opened at Rs. 867.90 and has touched a high and low of Rs. 883.00 and Rs. 855.05 respectively. So far 35,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1572.25 on 06-Feb-2017 and a 52 week low of Rs. 807.00 on 06-Dec-2017.
Last one week high and low of the scrip stood at Rs. 953.40 and Rs. 853.90 respectively. The current market cap of the company is Rs. 39,555.00 crore.
The promoters holding in the company stood at 47.02%, while Institutions and Non-Institutions held 37.64% and 15.35% respectively.
Lupin has launched Clobetasol Propionate Lotion 0.05% having received an approval from the United States Food and Drug Administration (USFDA) earlier. Clobetasol Propionate Lotion 0.05% had annual sales of around $12.6 million in the US (IQVIA MAT December 2017).
Lupin’s Clobetasol Propionate Lotion 0.05% is the generic equivalent of Galderma Labs’ Clobex lotion. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, in patients 18 years of age or older.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
